Intellia Therapeutics, Inc. (NTLA) is listed on NASDAQ in Medical Device Stocks. It is $12.87, -1.83%, with a $1.8B market cap. RSI is 57.8, neutral. The latest reported quarter missed estimates. Insiders were net sellers across the listed trades.
Technical Analysis
RSI (14) 57.8 Neutral
Market Cap $1.8B
Volume 2.3M
Fundamentals — 10-Q Q2 2026
Revenue $22.7M
Net Income $-202.9M
EPS $-1.61
Operating Margin -939.3%
Net Margin -893.4%
P/E Ratio -8.0x
Earnings
Recent Insider Trades
| Name | Title | Type | Shares | Price | Value | Date |
|---|---|---|---|---|---|---|
| Leonard John M | President and CEO | Sell | 22,675 | $12.65 | $286,819 | 2026 Aug 21 |
| Dulac Edward J III | EVP, Chief Financial Officer | Sell | 8,111 | $11.25 | $91,249 | 2026 Jul 22 |
| Dulac Edward J III | EVP, Chief Financial Officer | Sell | 4,677 | $18.00 | $84,186 | 2026 Jul 2 |
| Dube Michael P | VP, Chief Accounting Officer | Sell | 2,641 | $16.78 | $44,316 | 2026 Jul 1 |
| Clark Eliana | EVP, Chief Technical Officer | Sell | 607 | $13.78 | $8,364 | 2026 Mar 2 |
| Leonard John M | President and CEO | Sell | 88,146 | $9.49 | $836,384 | 2025 Dec 11 |
| Schultes Birgit C | EVP, Chief Scientific Officer | Sell | 31 | $17.38 | $539 | 2025 Oct 1 |
| Dube Michael P | VP, Chief Accounting Officer | Sell | 1,871 | $17.38 | $32,518 | 2025 Oct 1 |
| Chase William J | Director | Buy | 100,000 | $10.03 | $1.0M | 2025 Aug 20 |
| Dulac Edward J III | EVP, Chief Financial Officer | Sell | 7,462 | $14.02 | $104,617 | 2025 Jul 23 |
| Dube Michael P | VP, Chief Accounting Officer | Sell | 2,503 | $9.95 | $24,905 | 2025 Jul 2 |
| Clark Eliana | EVP, Chief Technical Officer | Sell | 1,022 | $9.82 | $10,036 | 2025 Jul 1 |
| Goodman Jesse | Director | Sell | 3,094 | $9.40 | $29,068 | 2025 Jul 1 |
| Bhanji Muna | Director | Sell | 265 | $8.50 | $2,253 | 2025 Apr 29 |
| Basta James | EVP, General Counsel | Sell | 2,572 | $8.99 | $23,122 | 2025 Mar 4 |
| Clark Eliana | EVP, Chief Technical Officer | Sell | 679 | $8.99 | $6,104 | 2025 Mar 4 |
| Bhanji Muna | Director | Sell | 265 | $9.97 | $2,642 | 2025 Jan 29 |
| Sepp-Lorenzino Laura | EVP, Chief Scientific Officer | Sell | 8,966 | $12.18 | $109,206 | 2025 Jan 3 |
| Hicks Derek | EVP, Chief Business Officer | Sell | 6,502 | $12.18 | $79,194 | 2025 Jan 3 |
| Lebwohl David | EVP, Chief Medical Officer | Sell | 9,557 | $12.18 | $116,404 | 2025 Jan 3 |
Other Medical Device Stocks
| Ticker | Price | RSI | Mkt Cap |
|---|---|---|---|
| | $46.83 | 45.9 | $67.9B |
| | $330.77 | 51.3 | $126.9B |
| | $91.21 | 57.7 | $116.7B |
| | $28.98 | 41.8 | -- |
Take NTLA further
- Browse Medical Device Stocks for the rest of the group, with what the businesses in it have in common and where they differ.
- Put NTLA in a portfolio and see what it does to total return, drawdown, and how the rest of your holdings move with it. Compares against the S&P 500 over the same days, free and without an account.
- Screen for others like it by RSI, valuation, market cap, and insider activity.
- Check the earnings calendar for when Intellia Therapeutics, Inc. next reports.
Set alerts on NTLA
Get notified when Intellia Therapeutics, Inc. hits your price targets or technical conditions are met.
Get Started Free